富祥药业
(300497)
| 流通市值：87.43亿 | | | 总市值：104.07亿 |
| 流通股本：4.53亿 | | | 总股本：5.39亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 471,507,621.46 | 482,977,340.02 | 632,736,892.59 | 606,508,100.18 |
| 交易性金融资产 | 816,500 | 954,500 | 1,978,000 | 2,185,000 |
| 应收票据及应收账款 | 466,639,332.79 | 417,179,148.03 | 295,970,799.01 | 279,800,662.04 |
| 其中：应收票据 | 50,064,327.52 | 46,930,513.43 | 24,490,274.82 | 27,664,255.58 |
| 应收账款 | 416,575,005.27 | 370,248,634.6 | 271,480,524.19 | 252,136,406.46 |
| 应收款项融资 | 152,677,928.92 | 116,108,242.64 | 124,067,621.11 | 165,605,297.04 |
| 预付款项 | 22,524,396.85 | 16,157,832.93 | 18,884,654.5 | 8,120,775.1 |
| 其他应收款合计 | 30,640,625.89 | 25,453,760.14 | 11,222,516.88 | 12,665,071.11 |
| 存货 | 381,664,092.76 | 379,932,713.34 | 406,039,083.61 | 471,593,590.6 |
| 其他流动资产 | 22,735,821.97 | 22,577,624.74 | 33,472,346.33 | 31,771,711.24 |
| 流动资产合计 | 1,549,206,320.64 | 1,461,341,161.84 | 1,524,371,914.03 | 1,578,250,207.31 |
| 非流动资产: | | | | |
| 长期股权投资 | 9,974,786.43 | 9,974,786.43 | 21,809,362.98 | 21,809,362.98 |
| 其他权益工具投资 | 183,275,859.12 | 183,275,859.12 | 150,994,909.7 | 150,994,909.7 |
| 其他非流动金融资产 | 78,063,294.67 | 78,063,294.67 | 78,383,367.2 | 78,383,367.2 |
| 投资性房地产 | 30,476,096.67 | 31,000,045.05 | 31,523,993.43 | 32,047,941.81 |
| 固定资产 | 1,813,192,364.03 | 1,860,786,811.9 | 1,684,389,636.03 | 1,726,260,522.59 |
| 在建工程 | 462,332,069.57 | 428,947,084.64 | 596,988,099.81 | 530,205,061.31 |
| 无形资产 | 285,639,181.97 | 287,852,820.28 | 289,309,175.33 | 291,159,341.46 |
| 递延所得税资产 | 35,042,358.43 | 34,802,956.89 | 31,099,535.07 | 29,985,692.69 |
| 其他非流动资产 | 32,094,414.49 | 28,690,443.82 | 29,029,045.39 | 42,834,641.17 |
| 非流动资产合计 | 2,930,090,425.38 | 2,943,394,102.8 | 2,913,527,124.94 | 2,903,680,840.91 |
| 资产总计 | 4,479,296,746.02 | 4,404,735,264.64 | 4,437,899,038.97 | 4,481,931,048.22 |
| 流动负债: | | | | |
| 短期借款 | 731,500,427.78 | 571,504,059.61 | 631,385,972.22 | 591,398,333.33 |
| 交易性金融负债 | 406,118.95 | - | - | - |
| 应付票据及应付账款 | 322,469,667.83 | 348,038,944.52 | 384,372,047.24 | 443,469,979.35 |
| 其中：应付票据 | 108,531,919.08 | 60,016,124.4 | 186,085,994.51 | 233,495,370.37 |
| 应付账款 | 213,937,748.75 | 288,022,820.12 | 198,286,052.73 | 209,974,608.98 |
| 预收款项 | 168,887.01 | 404,216.03 | 236,744.22 | 426,320.54 |
| 合同负债 | 3,751,563.95 | 2,025,966.44 | 3,049,936.43 | 2,224,471.22 |
| 应付职工薪酬 | 13,218,353.53 | 19,058,704.08 | 15,823,582.39 | 13,382,663.32 |
| 应交税费 | 13,873,641.65 | 7,105,981.58 | 10,686,086.38 | 8,609,453.89 |
| 其他应付款合计 | 68,368,447.79 | 12,286,396.04 | 5,352,842.22 | 6,131,911.54 |
| 一年内到期的非流动负债 | 69,340,000 | 270,020,000 | 260,900,000 | 260,900,000 |
| 其他流动负债 | 46,712,701.23 | 38,810,627.52 | 19,894,888.48 | 22,644,631.79 |
| 流动负债合计 | 1,269,809,809.72 | 1,269,254,895.82 | 1,331,702,099.58 | 1,349,187,764.98 |
| 非流动负债: | | | | |
| 长期借款 | 815,444,000 | 809,464,000 | 829,474,000 | 830,474,000 |
| 递延收益 | 123,207,228.69 | 123,972,778.08 | 106,886,525.7 | 104,403,968 |
| 递延所得税负债 | 1,839,128.86 | 1,862,849.47 | 1,886,570.1 | 1,910,290.7 |
| 非流动负债合计 | 940,490,357.55 | 935,299,627.55 | 938,247,095.8 | 936,788,258.7 |
| 负债合计 | 2,210,300,167.27 | 2,204,554,523.37 | 2,269,949,195.38 | 2,285,976,023.68 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 538,648,934 | 538,648,934 | 538,648,934 | 550,004,834 |
| 资本公积 | 1,248,577,453.53 | 1,247,068,457.73 | 1,247,068,457.73 | 1,381,102,767.24 |
| 减:库存股 | - | - | - | 174,858,651.95 |
| 其他综合收益 | 42,632,768.09 | 42,683,480.25 | 15,244,673.25 | 15,244,673.25 |
| 专项储备 | 1,955,632.72 | 1,650,599.84 | 1,572,845.33 | 1,354,597.47 |
| 盈余公积 | 144,261,996.51 | 144,261,996.51 | 144,261,996.51 | 144,261,996.51 |
| 未分配利润 | 270,685,907.82 | 209,490,398.63 | 201,764,418.36 | 257,604,793.78 |
| 归属于母公司股东权益合计 | 2,246,762,692.67 | 2,183,803,866.96 | 2,148,561,325.18 | 2,174,715,010.3 |
| 少数股东权益 | 22,233,886.08 | 16,376,874.31 | 19,388,518.41 | 21,240,014.24 |
| 股东权益合计 | 2,268,996,578.75 | 2,200,180,741.27 | 2,167,949,843.59 | 2,195,955,024.54 |
| 负债和股东权益合计 | 4,479,296,746.02 | 4,404,735,264.64 | 4,437,899,038.97 | 4,481,931,048.22 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-28 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |